Semaglutide generics regain momentum in July — but few brands lead the charge

The revival remains concentrated among a few companies, with 11 of the 33 brands accounting for 80 per cent of total sales volume. Leading the charge was Dr Reddy’s Obeda, whose sales more than doubled to 1.15 lakh units from 55,000 units in June.